A comprehensive comparison between in vivo and in vitro binding can be found in an excellent recent review [ 51].
Furthermore, binding can be regulated because interacting proteins recognise specific serine phosphorylation patterns in the CTD (reviewed in Buratkowski 2009).
Ligand binding can be divided into specific and nonspecific binding.
"All decisions can be judicially reviewed.
Other examples of allosteric binding have been observed for JNKs, PAK1, CHK1, CK2, GSK3-β, PKC-δ, and p38, and a discussion of their binding modes can be found in a recent comprehensive review.
These binding sites can be considered as prerequisite or allosteric binding sites.
Their judgment is not legally binding but can be used to apply pressure on states in human rights cases.
Data can be uploaded and reviewed retrospectively.
Alternatively, well expressed and proteolytically stable binding proteins selected from the non-antibody scaffold libraries can be used (for review see [ 42]).
What can be new, renewed and reviewed?
